CORMEDIX INC. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
CORMEDIX INC. (CRMD) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2026-08-13
- CORMEDIX INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2026-06-30 was $0.00.
- CORMEDIX INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2026-03-31 was -$1.00K.
- CORMEDIX INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-12-31 was -$3.70K.
- CORMEDIX INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-09-30 was $8.18K, a 62.32% increase year-over-year.
- CORMEDIX INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2025 was -$2.00K.
- CORMEDIX INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2024 was -$5.00K, a 151.64% decline from fiscal 2023.
- CORMEDIX INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2023 was $9.68K, a 91.55% increase from fiscal 2022.
- CORMEDIX INC. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2022 was $5.05K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | -$1.00K 10-Q · filed 2026-08-13 | -$4.70K derived: sum of 3 quarters · filed 2026-08-13 | $3.48K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | -$1.00K 10-Q · filed 2026-05-14 | -$4.70K derived: sum of 2 quarters · filed 2026-05-14 | $3.48K derived: sum of 3 quarters · filed 2026-05-14 | $1.48K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | -$3.70K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.48K derived: sum of 2 quarters · filed 2026-03-05 | $2.48K derived: sum of 3 quarters · filed 2026-08-13 | -$2.00K 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $8.18K 10-Q · filed 2025-11-12 | $6.18K derived: sum of 2 quarters · filed 2026-08-13 | $1.70K 10-Q · filed 2025-11-12 | $13.00 derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | -$2.00K 10-Q · filed 2026-08-13 | -$1.97K 10-Q · filed 2025-08-07 | -$6.00K 10-Q · filed 2026-08-13 | -$6.48K 10-Q · filed 2025-08-07 | -$8.17K derived: sum of 3 quarters · filed 2026-08-13 | -$3.13K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$5.00K 10-Q · filed 2026-05-14 | -$4.51K 10-Q · filed 2025-05-06 | -$6.17K derived: sum of 2 quarters · filed 2026-05-14 | -$1.13K derived: sum of 3 quarters · filed 2026-05-14 | $902.00 derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -$1.17K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.87K derived: sum of 2 quarters · filed 2026-03-05 | $5.90K derived: sum of 3 quarters · filed 2026-03-05 | -$5.00K 10-K · filed 2026-03-05 | -$4.83K 10-K · filed 2025-03-25 | ||
| 2024-09-30 | $5.04K 10-Q · filed 2025-11-12 | $7.07K derived: sum of 2 quarters · filed 2025-11-12 | -$3.83K 10-Q · filed 2025-11-12 | $4.76K derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $2.03K 10-Q · filed 2025-08-07 | -$8.87K 10-Q · filed 2025-08-07 | -$280.00 derived: sum of 3 quarters · filed 2025-08-07 | -$4.85K derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | -$10.90K 10-Q · filed 2025-05-06 | -$2.31K derived: sum of 2 quarters · filed 2025-05-06 | -$6.88K derived: sum of 3 quarters · filed 2025-05-06 | -$17.61K derived: sum of 4 quarters · filed 2025-05-06 | |||
| 2023-12-31 | $8.59K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $4.02K derived: sum of 2 quarters · filed 2025-03-25 | -$6.71K derived: sum of 3 quarters · filed 2025-03-25 | $9.68K 10-K · filed 2025-03-25 | |||
| 2023-09-30 | -$4.57K 10-Q · filed 2024-10-30 | -$15.30K derived: sum of 2 quarters · filed 2024-10-30 | $1.09K 10-Q · filed 2024-10-30 | $25.82K derived: sum of 4 quarters · filed 2024-10-30 | |||
| 2023-06-30 | -$10.73K 10-Q · filed 2024-08-14 | $5.66K 10-Q · filed 2024-08-14 | $30.39K derived: sum of 3 quarters · filed 2024-08-14 | $46.20K derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $16.39K 10-Q · filed 2024-05-09 | $41.13K derived: sum of 2 quarters · filed 2024-05-09 | $56.94K derived: sum of 3 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $24.73K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $40.54K derived: sum of 2 quarters · filed 2024-03-12 | $5.05K 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $15.81K 10-Q · filed 2023-11-14 | -$19.68K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |